Prevalence, Trends, and Distribution of Nicotine and Marijuana use in E-cigarettes among US adults: The Behavioral Risk Factor Surveillance System 2016-2018.


Journal

Preventive medicine
ISSN: 1096-0260
Titre abrégé: Prev Med
Pays: United States
ID NLM: 0322116

Informations de publication

Date de publication:
10 2020
Historique:
received: 10 01 2020
revised: 19 06 2020
accepted: 20 06 2020
pubmed: 1 7 2020
medline: 25 6 2021
entrez: 29 6 2020
Statut: ppublish

Résumé

Use of substances other than nicotine in e-cigarettes, especially marijuana, is becoming increasingly popular in the US. However, population-representative data on such poly-use (nicotine and marijuana) remains limited. We therefore conducted a cross-sectional logistic regression analysis of the 2018 Behavioral Risk Factor Surveillance System among 16 US states/territories with data on past 30-day marijuana use to describe the emerging dual nicotine and marijuana vaping population. We additionally examined trends in marijuana use, including marijuana vaping, from 2016 to 2018. Of the 131,807 participants studied, 3068 were current e-cigarette users, among whom 7.1% also vaped marijuana. Prevalence of nicotine-predominant, dual nicotine marijuana, and marijuana-predominant vaping was 3.36%, 0.38% and 1.09%, respectively. Compared to nicotine-predominant vapers, dual and marijuana-predominant vapers were older, had greater proportions of non-Whites, particularly Hispanics, and less likely to be current smokers (nicotine-predominant vs dual vs marijuana-predominant vaping: current tobacco use 44.7 vs 23.7 vs 11.1%). Proportion of dual vapers among current e-cigarette users was 8.6%, 2.6% and 7.1% for 2016, 2017 and 2018, respectively. Prevalence of marijuana use increased from 8.97% (2016) to 13.1% (2018) while no clear trend was observed for marijuana vaping. Dual nicotine and marijuana vaping is prevalent in the US, and compared to predominantly nicotine vapers such users have higher mean ages, and are more likely to be Blacks, Hispanics, and never cigarette smokers. Marijuana use overall increased from 2016 to 2018. Dual vapers represent a large and important emerging population that will require dedicated study of health effects and tailored regulatory strategies.

Identifiants

pubmed: 32593733
pii: S0091-7435(20)30199-7
doi: 10.1016/j.ypmed.2020.106175
pmc: PMC8383272
mid: NIHMS1729963
pii:
doi:

Substances chimiques

Nicotine 6M3C89ZY6R

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

106175

Subventions

Organisme : NHLBI NIH HHS
ID : K01 HL154130
Pays : United States
Organisme : NHLBI NIH HHS
ID : P50 HL120163
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007227
Pays : United States
Organisme : NHLBI NIH HHS
ID : U54 HL120163
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest Emelia J. Benjamin has received research grant from the NIH and American Heart Association (2U54HL120163). S. M. Iftekhar Uddin has received T32 grant from NIH (T32-HL-7227-44). All other authors have no financial disclosures or conflicts of interest.

Références

Subst Abuse. 2017 Sep 25;11:1178221817733736
pubmed: 28979131
Ann Intern Med. 2018 Oct 2;169(7):429-438
pubmed: 30167658
Tob Control. 2019 Mar;28(2):146-151
pubmed: 29853561
MMWR Morb Mortal Wkly Rep. 2019 Oct 04;68(39):845-850
pubmed: 31581164
Ann Intern Med. 2018 Dec 18;169(12):890-892
pubmed: 30167665
N Engl J Med. 2020 Feb 20;382(8):697-705
pubmed: 31860793
N Engl J Med. 2019 Oct 10;381(15):1488-1489
pubmed: 31491073
N Engl J Med. 2020 Mar 5;382(10):903-916
pubmed: 31491072
N Engl J Med. 2019 Oct 10;381(15):1490-1491
pubmed: 31532955
Nicotine Tob Res. 2020 Jul 16;22(8):1404-1408
pubmed: 31112595
J Policy Anal Manage. 2015 Winter;34(1):7-31
pubmed: 25558490
Am J Public Health. 2019 Feb;109(2):194-196
pubmed: 30649935

Auteurs

S M Iftekhar Uddin (SMI)

The American Heart Association Tobacco Regulation and Addiction Center, Dallas, TX, United States of America; Johns Hopkins University, Baltimore, MD, United States of America.

Albert D Osei (AD)

The American Heart Association Tobacco Regulation and Addiction Center, Dallas, TX, United States of America; Johns Hopkins University, Baltimore, MD, United States of America.

Olufunmilayo H Obisesan (OH)

The American Heart Association Tobacco Regulation and Addiction Center, Dallas, TX, United States of America; Johns Hopkins University, Baltimore, MD, United States of America.

Omar El-Shahawy (O)

The American Heart Association Tobacco Regulation and Addiction Center, Dallas, TX, United States of America; New York University, New York City, NY, United States of America.

Omar Dzaye (O)

Johns Hopkins University, Baltimore, MD, United States of America.

Miguel Cainzos-Achirica (M)

Johns Hopkins University, Baltimore, MD, United States of America.

Mohammadhassan Mirbolouk (M)

Johns Hopkins University, Baltimore, MD, United States of America; Yale New Haven Hospital, New Haven, CT, United States of America.

Olusola A Orimoloye (OA)

Johns Hopkins University, Baltimore, MD, United States of America; Vanderbilt University Medical Center, Nashville, TN, United States of America.

Andrew Stokes (A)

The American Heart Association Tobacco Regulation and Addiction Center, Dallas, TX, United States of America; Boston University, Boston, MA, United States of America.

Emelia J Benjamin (EJ)

The American Heart Association Tobacco Regulation and Addiction Center, Dallas, TX, United States of America; Boston University, Boston, MA, United States of America.

Aruni Bhatnagar (A)

The American Heart Association Tobacco Regulation and Addiction Center, Dallas, TX, United States of America; University of Louisville, Louisville, KY, United States of America.

Andrew P DeFilippis (AP)

The American Heart Association Tobacco Regulation and Addiction Center, Dallas, TX, United States of America; University of Louisville, Louisville, KY, United States of America.

Travis S Henry (TS)

University of California, San Francisco, San Francisco, CA, United States of America.

Khurram Nasir (K)

Johns Hopkins University, Baltimore, MD, United States of America; Houston Methodist Hospital, Houston, TX, United States of America.

Michael J Blaha (MJ)

The American Heart Association Tobacco Regulation and Addiction Center, Dallas, TX, United States of America; Johns Hopkins University, Baltimore, MD, United States of America. Electronic address: mblaha1@jhmi.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH